Initial agonist treatment of Parkinson disease
- 11 February 2003
- journal article
- review article
- Published by Wolters Kluwer Health in Neurology
- Vol. 60 (3) , 390-394
- https://doi.org/10.1212/01.wnl.0000052681.28286.52
Abstract
The evidence supporting initial dopamine agonist treatment of PD is reviewed. The two rationales for initial agonist treatment are reduced frequency of motor complications and possible relative neuroprotection by dopamine agonists. The basic science supporting these rationales is equivocal. The clinical evidence for advantages of initial agonist treatment is incomplete. More data are required to determine the optimal initial treatment for PD.Keywords
This publication has 32 references indexed in Scilit:
- Increase in Dopamine Turnover Occurs Early in Parkinson's Disease: Evidence from a New Modeling Approach to PET 18F-Fluorodopa DataJournal of Cerebral Blood Flow & Metabolism, 2002
- Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnoverAnnals of Neurology, 2001
- Pramipexole attenuates the dopaminergic cell loss induced by intraventricular 6-hydroxydopamineJournal Of Neural Transmission-Parkinsons Disease and Dementia Section, 2000
- Effect of treatment withL-dopa/carbidopa orL-selegiline on striatal dopamine transporter SPECT imaging with [123I]?-CITMovement Disorders, 1999
- Chronic levodopa is not toxic for remaining dopamine neurons, but instead promotes their recovery, in rats with moderate nigrostriatal lesionsAnnals of Neurology, 1998
- De novo administration of ropinirole and bromocriptine induces less dyskinesia than L‐dopa in the MPTP‐treated marmosetMovement Disorders, 1998
- Early Treatment of Parkinson??s Disease with Cabergoline Delays the Onset of Motor ComplicationsDrugs, 1998
- The response to levodopa in parkinson's disease: Imposing pharmacological law and orderAnnals of Neurology, 1996
- Does selegiline delay progression of Parkinson's disease? A critical re-evaluation of the DATATOP study.Journal of Neurology, Neurosurgery & Psychiatry, 1994
- Continuous and intermittent levodopa differentially affect basal ganglia functionAnnals of Neurology, 1989